| Amber Lynn Zimmer, CNM, APRN | |
|
2032 E 22nd St, Casper, WY 82601-5081 | |
| (307) 262-5134 | |
| (331) 204-1133 |
| Full Name | Amber Lynn Zimmer |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 2032 E 22nd St, Casper, Wyoming |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235677683 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 28533 (Wyoming) | Secondary |
| 367A00000X | Advanced Practice Midwife | 28533.1604 (Wyoming) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Amber Lynn Zimmer, CNM, APRN 2032 E 22nd St, Casper, WY 82601-5081 Ph: (307) 262-5134 | Amber Lynn Zimmer, CNM, APRN 2032 E 22nd St, Casper, WY 82601-5081 Ph: (307) 262-5134 |
News Archive
Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, announced today that it has signed a licensing agreement with the international pharmaceutical company Boehringer Ingelheim. The deal will aim to further extend marketing of Marinomed's anti-viral nasal spray for the treatment of the Common Cold to all of Europe (except Austria and UK), Russia and CIS, South America, parts of Asia and Australia.
Around 600,000 Austrians suffer from diabetes. This condition is frequently associated with serious retinal disorders. Along with age-related macular degeneration, diabetic retinal degeneration is one of the most common causes of blindness. The Department of Ophthalmology and Optometry at MedUni Vienna was chosen by the European Society of Retina Specialists (EURETINA) to coordinate the development of up-to-date treatment and diagnostic guidelines.
InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries and other neurotrauma conditions, today announced that the U.S. Food and Drug Administration has approved the Company's Investigational Device Exemption to begin human studies to test its biopolymer scaffold product, a technology developed to treat patients with acute, traumatic SCI.
Ventrus Biosciences Inc., a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the pricing of its initial public offering of 2,900,000 shares at $6.00 per share. The shares are expected to begin trading tomorrow, December 17, 2010 on the Nasdaq Capital Market under the symbol "VTUS". In addition, Ventrus has granted the underwriters a 45-day option to purchase up to an additional 435,000 shares to cover over-allotments, if any.
› Verified 2 days ago
Tara Blumenshine, APRN, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 5000 Blackmore Rd, Casper, WY 82609 Phone: 307-233-6000 Fax: 307-233-6089 |